Hugh Goodfellow leads the life sciences team at Carpmaels & Ransford LLP, spending much of his time overseeing teams of attorneys who assist innovator companies in protecting their commercial products. Accordingly, he has a large prosecution practice and is a regular visitor to the European Patent Office (EPO), handling many oppositions and appeals. With so many projects running in parallel between the EPO and national litigation, he also forms a cornerstone of Carpmaels’ dispute resolution practice. He has extensive experience of patent prosecution in countries outside Europe and has pan-European expertise in the filing, prosecution and defence of supplementary protection certificates nationally, as well as considerable experience and success before the European Court of Justice.
Dr. Goodfellow’s direct clients range from biotech companies in the United Kingdom and continental Europe, through to large and long-established global companies. He has also been responsible for establishing the filing strategy and generating IP portfolios for a number of start-ups. His particular areas of current focus include biologics – in particular, therapeutic antibodies, complex immunology, biosimilars and stem cells. Collectively, these experiences provide him with the ability both to protect foundation IP as broadly as possible and to forecast potential future problems from the viewpoint of both IP generation and freedom to operate.